Constriction

U.S. FDA Approves OPSYNVI® (macitentan and tadalafil) as the First and Only Once-Daily Single-Tablet Combination Therapy for Patients with Pulmonary Arterial Hypertension (PAH)

Retrieved on: 
Friday, March 22, 2024
Diagnosis, ESC, Toxicity, ERA, Tadalafil, Internal medicine, European Respiratory Society, Disease, Risk, Pulmonary hypertension, Patient, PVR, Mitigation, Female, Nitric oxide, Connective tissue disease, Orthostatic hypertension, World Health Organization, PDE5, Johnson & Johnson, REMS, WHO, Pulmonary circulation, PAH, FDA, Constriction, ERS, Food, Pharmaceutical industry

RARITAN, N.J., March 22, 2024  /PRNewswire/ -- Johnson & Johnson today announced that the U.S. Food and Drug Administration (FDA) has approved OPSYNVI® – a single-tablet combination of macitentan, an endothelin receptor antagonist (ERA), and tadalafil, a phosphodiesterase 5 (PDE5) inhibitor – for the chronic treatment of adults with pulmonary arterial hypertension (PAH, World Health Organization [WHO] Group I) and WHO functional class (FC) II-III.1 OPSYNVI® may be used in patients with PAH who are treatment-naïve or who are already on an ERA, PDE5 inhibitor or both. OPSYNVI® may be used in patients who are currently treated concomitantly with stable doses of macitentan 10 mg and tadalafil 40 mg (20 mg x 2) as separate tablets.1

Key Points: 
  • Historically, this required patients to take multiple pills because no single-tablet combination therapy targeting two or more pathways was available," said Kelly Chin, M.D., Professor of Internal Medicine and Director of the Pulmonary Hypertension Program at UT Southwestern Medical Center, and an investigator in the A DUE study.
  • The FDA's approval of OPSYNVI® is based on the results from the pivotal Phase 3 A DUE study , in which OPSYNVI® demonstrated greater reduction in Pulmonary Vascular Resistance (PVR) after 16 weeks versus tadalafil or macitentan monotherapy.
  • "People with PAH often live with the burden of taking many pills each day, which can pose challenges," said James F. List, M.D., Ph.D., Global Therapeutic Area Head, whose team oversees a portfolio of programs including Pulmonary Hypertension at Johnson & Johnson.
  • "We're thrilled to bring this single-tablet combination therapy to patients, as it has the potential to optimize disease management and fulfill a significant unmet need in supporting recently updated treatment guidelines that call for initial or early combination treatment."

ASLAN Pharmaceuticals Announces New Translational Data on Eblasakimab in COPD and Appoints Leading Respiratory Experts as Scientific Advisors

Retrieved on: 
Wednesday, March 6, 2024
Translational medicine, SAN, MD, Emergency medicine, Partnership, Atopic dermatitis, Asthma, Chronic obstructive pulmonary disease, Rutgers University, Formoterol, Associate, Patient, Disease, Constriction, Harvard Medical School, ASLN, Pharmaceutical industry

“I’m delighted to work with the ASLAN team on this exciting opportunity to evaluate development paths for eblasakimab in COPD, a Type 2-driven disease.

Key Points: 
  • “I’m delighted to work with the ASLAN team on this exciting opportunity to evaluate development paths for eblasakimab in COPD, a Type 2-driven disease.
  • In November 2023, ASLAN announced translational data from healthy donor tissue that suggested eblasakimab’s potential as a COPD therapeutic to inhibit Type 2 inflammation.
  • Further studies have been conducted using lung tissue from a COPD patient, comparing the same concentrations of eblasakimab and dupilumab.
  • Further translational data on eblasakimab in COPD will be submitted for publication at upcoming scientific congresses.

Herbal medicinal product: Lini semenArray, C: ongoing call for scientific data

Retrieved on: 
Tuesday, March 12, 2024
Key, Adolescence, Committee, Monograph, Paralysis, Plant, Date, Seed, Mouth, Constipation, Stomach, Safety, Allergy, Patient, Medicine, Constriction, Bleeding, Herbal medicine, Trial of the century, Ageing, Irritation, Water, Dietary supplement

Herbal medicinal product: Lini semenArray, C: ongoing call for scientific data

Key Points: 


Herbal medicinal product: Lini semenArray, C: ongoing call for scientific data

Government of Canada's Interest Cap Risks Criminal Surge

Retrieved on: 
Monday, February 5, 2024
Police, Policy, Crime, Constriction, CNW, Legislation, Vacuum, CLA, Office, Government, APR, Federation, Risk, Human, Credit

"Under the legislation, illegal predatory lenders could take advantage of Canadians by operating online from outside the bounds of Canadian jurisdiction.

Key Points: 
  • "Under the legislation, illegal predatory lenders could take advantage of Canadians by operating online from outside the bounds of Canadian jurisdiction.
  • By forcing legal, responsible lenders out of the marketplace, we worry Canadians will be targeted by this type of criminal activity."
  • The comprehensive study further highlights:
    The government's proposed interest rate reduction from 47% to 35% APR will restrict access to essential credit for approximately 4.7 million Canadians.
  • International case studies from Quebec California and the UK reveal the outcomes of lowering interest rates are diverse and complex.

JBTC Announces 4th Quarter 2023 Earnings

Retrieved on: 
Tuesday, January 23, 2024
OTCQX, Constriction

JONESTOWN, Pa., Jan. 23, 2024 (GLOBE NEWSWIRE) -- JBT Bancorp, Inc. (OTCQX: JBTC) reported quarterly earnings of $2,073,000 with earnings per share of $0.85.

Key Points: 
  • JONESTOWN, Pa., Jan. 23, 2024 (GLOBE NEWSWIRE) -- JBT Bancorp, Inc. (OTCQX: JBTC) reported quarterly earnings of $2,073,000 with earnings per share of $0.85.
  • Earnings were down 6.92% compared to the final quarter of 2022.
  • Full-year unaudited earnings were $7,793,000 with earnings per share of $3.20.
  • Earnings fell 3.31% from $8,060,000 and earnings per share were down from $3.31 in the prior year.

World Canned Oxygen Market Shares, Strategy, and Forecasts Report 2023: Markets at $103 Million in 2022 are Anticipated to Achieve Rapid Growth of 91.3% CAGR through 2029 - ResearchAndMarkets.com

Retrieved on: 
Friday, January 5, 2024
General Health, Health, Chemicals, Plastics, Food, Beverage, Fitness & Nutrition, Manufacturing, Retail, Other Health, Heart, Constriction, Growth, Fatigue, Exercise, Carbon, Athlete, Oxygen saturation (medicine), Oxygen, Research

The "Canned Oxygen: Market Shares, Strategies, and Forecasts, 2023 to 2029" report from Wintergreen Research, Inc has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Canned Oxygen: Market Shares, Strategies, and Forecasts, 2023 to 2029" report from Wintergreen Research, Inc has been added to ResearchAndMarkets.com's offering.
  • Canned oxygen markets at $103 million in 2022 are anticipated to achieve rapid growth of 91.3% CAGR through 2029.
  • Canned oxygen provides new markets for the soda bottling and beer companies, among others.
  • Squirts of oxygen help athletes recover from energy depletion at the end of a sprint.

Sosei Group Announces Marketing Approval for PIVLAZ™ (clazosentan sodium) 150 mg in South Korea

Retrieved on: 
Thursday, December 7, 2023
Marketing, Artery, Hospital, Cerebral vasospasm, Neurosurgery, Culture of Korea, IPJ, Rupture, Physician, Acquisition, Bleeding, Mortality, SubArachnoid Space, Brain, Incidence, Subarachnoid hemorrhage, Death, Ministry, Constriction, Aneurysm, IPK, Patient, MFDS, Pharmaceutical industry

Tokyo, Japan, Seoul, South Korea, and Cambridge, UK, 7 December 2023 – Sosei Group Corporation (“Sosei Heptares” or “the Company”; TSE: 4565) today announces that PIVLAZ™ (clazosentan sodium) 150 mg has received marketing approval from the Ministry of Food and Drug Safety (MFDS) in South Korea for the prevention of cerebral vasospasm, vasospasm-related cerebral infarction, and cerebral ischemic symptoms after aneurysmal subarachnoid hemorrhage (aSAH) securing.

Key Points: 
  • Tokyo, Japan, Seoul, South Korea, and Cambridge, UK, 7 December 2023 – Sosei Group Corporation (“Sosei Heptares” or “the Company”; TSE: 4565) today announces that PIVLAZ™ (clazosentan sodium) 150 mg has received marketing approval from the Ministry of Food and Drug Safety (MFDS) in South Korea for the prevention of cerebral vasospasm, vasospasm-related cerebral infarction, and cerebral ischemic symptoms after aneurysmal subarachnoid hemorrhage (aSAH) securing.
  • The MFDS approval is based on scientific and clinical data from an extensive Japanese Phase 3 program submitted by Idorsia Pharmaceuticals Korea (“IPK”), a Sosei Group company.
  • In South Korea, the Marketing Authorization of PIVLAZ™ is held by IPK and will become commercially available to patients in early 2025.
  • PIVLAZ™ received marketing approval in Japan in January 2022 and was launched in April 2022 by Idorsia Pharmaceuticals Japan ("IPJ”), also a Sosei Group company.

Penn Highlands Healthcare Physician Embraces Robotic Technology: First In Region To Robotically Remove a Bladder and Create a Urinary Diversion

Retrieved on: 
Tuesday, December 5, 2023
Urine, General surgery, Bleeding, The Jetsons, Urethra, Lymph, Movement, Bladder cancer, Robotics, Male, Surgeon, Star Wars, Prostate cancer, Green-light, MD, Urinary diversion, Prostate, System, Ureteroscopy, Constriction, Prostatic urethral lift, Scar, Television, Cancer, Patient, Medicine, Female, R2-D2

Dr. Banerji recently completed his100th robotic case, which was a radical prostatectomy – surgery to remove the entire prostate gland and surrounding lymph nodes -- on a man with localized prostate cancer.

Key Points: 
  • In 2021, surgeons at Penn Highlands Healthcare began using the advanced da Vinci Xi robotic-assisted surgical system to perform a wide range of delicate and complex operations.
  • Today, in addition to being used for general surgery, the da Vinci robot is assisting surgeons who perform urologic, colorectal and gynecologic surgeries at Penn Highlands DuBois.
  • John S. Banerji, MD, a physician with Penn Highlands Urology in Clearfield and DuBois, Pennsylvania, has been using the robotic-assisted system for his surgeries.
  • While some surgeons remove the bladder robotically and then convert to open surgery for the urinary diversion, Dr. Banerji performed the entire surgical procedure robotically.

Environmental Noise Control, Inc. Products Now Featured on New York Department of Environmental Protection's Approved List

Retrieved on: 
Tuesday, December 5, 2023
Environmental protection, STC, RCNY, DEP, Constriction, Noise, ENC

Being added to the select list of NY DEP-approved products is an honor for ENC.

Key Points: 
  • Being added to the select list of NY DEP-approved products is an honor for ENC.
  • Environmental Noise Control has a fleet of noise control products that are manufactured in-house and range from temporary sound wall systems to portable panels and acoustic blankets.
  • "We are thrilled to have our products included in the NY DEP's approved list," says Don Behrens, Founder and President of Environmental Noise Control.
  • Environmental Noise Control offers acoustic blankets, wind-rated acoustical barriers up to 40' tall, and free-standing panels that exceed this requirement.

ASLAN Pharmaceuticals Presents New Data on Eblasakimab in Atopic Dermatitis and COPD Translational Models at the 7th Dermatology Drug Development Summit

Retrieved on: 
Friday, November 3, 2023
Drug development, Type, AD, Dermatology, Eosinophilic bronchitis, Duke University, Johns Hopkins School of Medicine, Mortality, Cytokine, CCL3, Research, Inflammation, DDDS, Dupilumab, Research fellow, Biology, Constriction, ASLN, Chemokine, Head, AHR, Atopic dermatitis, International Society, Patient, Chronic obstructive pulmonary disease, CCL4, SAN, Pharmaceutical industry, COPD

ASLAN also presented new data investigating the role of eblasakimab in COPD using an established ex vivo model of precision cut lung slices from human donors2.

Key Points: 
  • ASLAN also presented new data investigating the role of eblasakimab in COPD using an established ex vivo model of precision cut lung slices from human donors2.
  • The model tested airway hyperresponsiveness (AHR) in the lung tissue using IL-4 and IL-13, the key Th2 cytokines involved in COPD disease pathology3.
  • Furthermore, IL-4 and IL-13 sensitized the airways to further constriction in response to methacholine, but this sensitization was blocked by eblasakimab treatment.
  • The presentation from Drug Development Summit can be accessed via the ASLAN website here .